Download - Lymphoma s
![Page 1: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/1.jpg)
Lymphomas
S. Sami Kartı, MD, Prof.
![Page 2: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/2.jpg)
Conceptualizing lymphoma
neoplasms of lymphoid origin, typically causing lymphadenopathy
![Page 3: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/3.jpg)
ALLALL MM MM CLLCLL LymphomasLymphomas
Hematopoieticstem cell
Neutrophils
Eosinophils
Basophils
Monocytes
Platelets
Red cells
Myeloidprogenitor
Myeloproliferative disordersMyeloproliferative disordersAMLAML
Lymphoidprogenitor T-lymphocytes
Plasmacells
B-lymphocytes
nanaïïveve
![Page 4: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/4.jpg)
B-cell development
stemcell
lymphoidprogenitor
progenitor-B
pre-B
immatureB-cell
memoryB-cell
plasma cellplasma cell
DLBCL,FL, HL
ALL
CLL
MM
germinalgerminalcentercenterB-cellB-cell
maturenaiveB-cell
![Page 5: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/5.jpg)
Clinically useful classification
Diseases that have distinct• clinical features• natural history• prognosis• treatment
Biologically rational classification
Diseases that have distinct• morphology• immunophenotype• genetic features• clinical features
Classification
![Page 6: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/6.jpg)
Lymphoma classification (2001 WHO)
B-cell neoplasms precursor mature
T-cell & NK-cell neoplasms precursor mature
Hodgkin lymphoma
Non-HodgkinLymphomas
![Page 7: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/7.jpg)
A practical way to think of lymphoma
Category Survival of untreated patients
Curability To treat or not to treat
Non-Hodgkin lymphoma
Indolent Years Generally not curable
Generally defer Rx if asymptomatic
Aggressive Months Curable in some
Treat
Very aggressive
Weeks Curable in some
Treat
Hodgkin lymphoma
All types Variable – months to years
Curable in most
Treat
![Page 8: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/8.jpg)
Mechanisms of lymphomagenesis
Genetic alterations Infection Antigen stimulation Immunosuppression
![Page 9: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/9.jpg)
Epidemiology of lymphomas
5th most frequently diagnosed cancer in both sexes
males > females incidence
NHL increasing Hodgkin lymphoma stable
![Page 10: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/10.jpg)
Risk factors for NHL
immunosuppression or immunodeficiency
connective tissue disease family history of lymphoma infectious agents ionizing radiation
![Page 11: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/11.jpg)
Clinical manifestations Variable
severity: asymptomatic to extremely ill time course: evolution over weeks, months, or
years
Systemic manifestations fever, night sweats, weight loss, anorexia, pruritis
Local manifestations lymphadenopathy, splenomegaly most common any tissue potentially can be infiltrated
![Page 12: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/12.jpg)
Other complications of lymphoma
bone marrow failure (infiltration) CNS infiltration immune hemolysis or
thrombocytopenia compression of structures (eg spinal
cord, ureters) pleural/pericardial effusions, ascites
![Page 13: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/13.jpg)
Diagnosis requires an adequate biopsy
Diagnosis should be biopsy-proven before treatment is initiated
Need enough tissue to assess cells and architecture open bx vs core needle bx vs FNA
![Page 14: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/14.jpg)
Stage I Stage II Stage III Stage IV
Staging of lymphoma
A: absence of B symptomsB: fever, night sweats, weight loss
![Page 15: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/15.jpg)
Three common lymphomas
Diffuse large B-cell lymphoma Follicular lymphoma Hodgkin lymphoma
![Page 16: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/16.jpg)
Relative frequencies of different lymphomas
Hodgkinlymphoma
NHL
Diffuse large B-cell
Follicular
Other NHL
Non-Hodgkin Lymphomas
~85% of NHL are B-lineage
![Page 17: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/17.jpg)
Follicular lymphoma most common type of “indolent”
lymphoma usually widespread at presentation often asymptomatic not curable (some exceptions) associated with BCL-2 gene
rearrangement [t(14;18)] cell of origin: germinal center B-cell
![Page 18: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/18.jpg)
defer treatment if asymptomatic (“watch-and-wait”)
several chemotherapy options if symptomatic
median survival: years despite “indolent” label, morbidity
and mortality can be considerable transformation to aggressive
lymphoma can occur
![Page 19: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/19.jpg)
Diffuse large B-cell lymphoma
![Page 20: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/20.jpg)
Introduction
most common type of “aggressive” lymphoma
extranodal involvement is common cell of origin: germinal center B-cell
![Page 21: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/21.jpg)
Clinical presentation
Usually presents with one or more rapidly growing tumor masses involving nodal or extranodal sites
Not tender Usually not interfere organ function
except by compression
![Page 22: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/22.jpg)
Treatment
Chemotherapy Radiotherapy Chemotherapy + radiotherapy Autologous or allogeneic stem cell
transplantation in relaps or refractory cases
![Page 23: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/23.jpg)
Hodgkin lymphoma
Thomas Hodgkin(1798-1866)
![Page 24: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/24.jpg)
Classical Hodgkin Lymphoma
![Page 25: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/25.jpg)
Hodgkin lymphoma
cell of origin: germinal centre B-cell Reed-Sternberg cells (or RS variants)
in the affected tissues most cells in affected lymph node are
polyclonal reactive lymphoid cells, not neoplastic cells
![Page 26: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/26.jpg)
Reed-Sternberg cell
![Page 27: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/27.jpg)
RS cell and variants
popcorn celllacunar cellclassic RS cell
![Page 28: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/28.jpg)
A possible model of pathogenesis
germinalcentreB cell
transformingevent(s)
loss of apoptosis
RS cellinflammatory
response
EBV?
cytokines
![Page 29: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/29.jpg)
Histologic subtypes
Classical Hodgkin lymphoma nodular sclerosis (most common subtype) mixed cellularity lymphocyte-rich lymphocyte depleted
![Page 30: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/30.jpg)
Epidemiology
less frequent than non-Hodgkin lymphoma
overall M>F peak incidence in 3rd decade
![Page 31: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/31.jpg)
Associated (etiological?) factors
EBV infection smaller family size higher socio-economic status caucasian > non-caucasian possible genetic predisposition other: HIV? occupation? herbicides?
![Page 32: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/32.jpg)
Clinical manifestations
lymphadenopathy extranodal sites relatively uncommon
except in advanced disease “B” symptoms
![Page 33: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/33.jpg)
Treatment and Prognosis
Stage Treatment Overall 5 year
survival
I,II ABVD x 2-4 & radiation
80-90%
III,IV ABVD x 6-8 70-80%
![Page 34: Lymphoma s](https://reader036.vdocument.in/reader036/viewer/2022081603/56814f2c550346895dbcb805/html5/thumbnails/34.jpg)
Long term complications of treatment
infertility MOPP > ABVD; males > females sperm banking should be discussed premature menopause
secondary malignancy skin, AML, lung, MDS, NHL, thyroid,
breast... cardiac disease